1599P - Ambulatory patients with metastatic or locally advanced cancer: is body mass index ≥ 35 a risk factor for thromboembolism also in European countri...
|Date||01 October 2012|
|Event||ESMO Congress 2012|
|Session||Poster presentation III|
|Topics|| Supportive Care
Cancer Aetiology, Epidemiology, Prevention
S. Barni1, R. Labianca2, G. Gasparini3, E. Bonizzoni4, F. Petrelli5, T. Perrone6, M. Verso7
Five variables (site of cancer, platelet count, haemoglobin level, leukocyte count and body mass index [BMI]) define the Khorana risk score, predicting the high (≥ 3), the moderate (1-2) and the low (0) risk of thromboembolic events (TE) in cancer outpatients. This score has validated BMI ≥ 35 as a risk factors for TE in the USA.Methods
The aim of our retrospectively study was to evaluate the incidence of a BMI ≥ 35 (obesity of second and third class), a BMI ≥ 30 (obesity of all classes) and a BMI ≥ 25 (all forms of overweight) among 1150 ambulatory cancer patients receiving chemotherapy enrolled in the PROTECHT study: a randomized, double-blind, placebo-controlled study, evaluating the efficacy (incidence of symptomatic TE) of subcutaneous injections of nadroparin (3800 IU anti-Xa once a day). We evaluated also the distribution of TE among the three BMI categories.Results
are reported in the table below as percentage and (Number of patients) for BMI distribution and number of detected TE for each BMI class:
|BMI ≥ 35||BMI ≥30||BMI ≥25|
|PLACEBO 381 pts||1.3 (5)||1||13.4 (51)||2||51.2 (195)||5|
|NADROPARIN 769 pts||2.6 (20)||0||14.0 (108)||1||49.0 (377)||9|
In our study nearly 50% of patients with metastatic or locally advanced diagnosis of cancer are overweight and more than 25% of them are obese. The incidence of BMI ≥ 35 in a European cancer population seems to be negligible, otherwise all classes of overweight seems to be related to a higher risk of TE. A formal study is needed to evaluate the risk of all BMI classes as independent risk factors of TE among cancer patients.Disclosure
T. Perrone: TP is employee of Italfarmaco S.p.A.
All other authors have declared no conflicts of interest.